a public good project by the
Synthesis
Company
of California

© 2026

Daniel E. Everitt | doi.page

0 works0 citations0 h-index

Daniel E. Everitt

TB Alliance(US)

Publications by Year

Research Areas

Tuberculosis Research and Epidemiology, Pneumonia and Respiratory Infections, Mycobacterium research and diagnosis, Glaucoma and retinal disorders, Pneumocystis jirovecii pneumonia detection and treatment

Most-Cited Works

→ Treatment of Highly Drug-Resistant Pulmonary Tuberculosis(2020)985 cited
→ Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis(2022)528 cited
→ 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial(2012)429 cited
→ A Randomized Trial of a Program to Reduce the Use of Psychoactive Drugs in Nursing Homes(1992)402 cited
→ A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis(2004)276 cited
→ Treatment for glaucoma: adherence by the elderly.(1993)267 cited
→

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

(2015)

249 cited

→ An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis(2006)226 cited

→ Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline(2015)200 cited

→ Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis(2007)193 cited